Trader Harvard Bioscience - HBIO CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.0350 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Harvard Bioscience Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 5.5929 |
| Ouvert* | 5.6628 |
| Variation sur 1 an* | 51.41% |
| Fourchette du jour* | 5.6628 - 5.9824 |
| Fourchette sur 52 semaines | 1.98-6.29 |
| Volume moyen (10 jours) | 213.48K |
| Volume moyen (3 mois) | 4.01M |
| Capitalisation boursière | 248.08M |
| Ratio C/B | -100.00K |
| Actions en circulation | 42.19M |
| Revenu | 114.53M |
| EPS | -0.05 |
| Dividende (rendement en %) | N/A |
| Bêta | 1.68 |
| Prochaine date de publication des résultats | Aug 1, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 5.8725 | 0.3797 | 6.91% | 5.4928 | 5.9824 | 5.4928 |
| May 25, 2023 | 5.5929 | 0.1400 | 2.57% | 5.4529 | 5.6028 | 5.3631 |
| May 24, 2023 | 5.6728 | 0.0401 | 0.71% | 5.6327 | 5.7227 | 5.3631 |
| May 23, 2023 | 5.6728 | -0.1897 | -3.24% | 5.8625 | 5.9125 | 5.6328 |
| May 22, 2023 | 5.8625 | 0.1799 | 3.17% | 5.6826 | 5.9025 | 5.6826 |
| May 19, 2023 | 5.7427 | 0.2098 | 3.79% | 5.5329 | 5.9424 | 5.4630 |
| May 18, 2023 | 5.5629 | -0.0599 | -1.07% | 5.6228 | 5.6228 | 5.4131 |
| May 17, 2023 | 5.6228 | 0.2598 | 4.84% | 5.3630 | 5.6628 | 5.3630 |
| May 16, 2023 | 5.4131 | 0.3197 | 6.28% | 5.0934 | 5.4730 | 5.0934 |
| May 15, 2023 | 5.3232 | -0.2995 | -5.33% | 5.6227 | 5.6228 | 5.0835 |
| May 12, 2023 | 5.5829 | -0.1398 | -2.44% | 5.7227 | 5.8326 | 5.4930 |
| May 11, 2023 | 5.7127 | 0.3197 | 5.93% | 5.3930 | 5.7427 | 5.3731 |
| May 10, 2023 | 5.5829 | -0.1397 | -2.44% | 5.7226 | 5.8226 | 5.5130 |
| May 9, 2023 | 5.7127 | -0.0598 | -1.04% | 5.7725 | 5.8026 | 5.3431 |
| May 8, 2023 | 5.8825 | -0.2597 | -4.23% | 6.1422 | 6.2021 | 5.8225 |
| May 5, 2023 | 6.1222 | -0.0599 | -0.97% | 6.1821 | 6.1821 | 6.0023 |
| May 4, 2023 | 6.1122 | 0.1099 | 1.83% | 6.0023 | 6.2321 | 5.9923 |
| May 3, 2023 | 6.0922 | -0.0500 | -0.81% | 6.1422 | 6.1422 | 5.8025 |
| May 2, 2023 | 6.0623 | 0.1699 | 2.88% | 5.8924 | 6.2520 | 5.7126 |
| May 1, 2023 | 5.9325 | 0.3198 | 5.70% | 5.6127 | 6.0723 | 5.6127 |
Harvard Bioscience Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Tuesday, August 1, 2023 | ||
| Heure (UTC) (UTC) 20:00 | Pays US
| Événement Q2 2023 Harvard Bioscience Inc Earnings Release Q2 2023 Harvard Bioscience Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q3 2023 Harvard Bioscience Inc Earnings Release Q3 2023 Harvard Bioscience Inc Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 113.335 | 118.904 | 102.1 | 116.176 | 120.774 |
| Revenu | 113.335 | 118.904 | 102.1 | 116.176 | 120.774 |
| Coût des recettes, total | 51.045 | 51.252 | 44.059 | 51.654 | 53.793 |
| Résultat brut | 62.29 | 67.652 | 58.041 | 64.522 | 66.981 |
| Total des frais d'exploitation | 120.268 | 116.838 | 103.755 | 115.799 | 123.19 |
| Total des frais de vente/Généraux/Admin | 48.611 | 47.672 | 43.425 | 45.324 | 45.825 |
| Recherche et développement | 12.329 | 10.799 | 8.685 | 10.715 | 10.988 |
| Depreciation / Amortization | 6.122 | 5.84 | 5.71 | 5.746 | 5.384 |
| Charges (revenus) inhabituelles | 2.161 | 1.275 | 1.876 | 2.36 | 7.2 |
| Produits d'exploitation | -6.933 | 2.066 | -1.655 | 0.377 | -2.416 |
| Produits (charges) d'intérêts, nets Hors exploitation | -2.548 | -1.54 | -4.831 | -5.41 | -5.219 |
| Autres, nets | 0.302 | -0.666 | -0.806 | -0.469 | -0.34 |
| Résultat net avant impôts | -9.179 | -0.14 | -7.292 | -5.502 | -7.975 |
| Résultat net après impôts | -9.516 | -0.288 | -7.81 | -4.687 | -4.299 |
| Résultat net avant éléments extra | -9.516 | -0.288 | -7.81 | -4.687 | -4.299 |
| Résultat net | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -9.516 | -0.288 | -7.81 | -4.687 | -4.299 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Résultat net dilué | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Moyenne pondérée des actions diluées | 41.413 | 40.343 | 38.64 | 37.814 | 36.453 |
| BPA dilué hors éléments extraordinaires | -0.22978 | -0.00714 | -0.20212 | -0.12395 | -0.11793 |
| BPA dilué normalisé | -0.19586 | 0.0134 | -0.13637 | -0.08338 | 0.01045 |
| Total des éléments extraordinaires | 0 | 1.377 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 29.975 | 28.427 | 26.922 | 29.208 | 28.778 |
| Revenu | 29.975 | 28.427 | 26.922 | 29.208 | 28.778 |
| Coût des recettes, total | 11.629 | 12.594 | 14.75 | 12.571 | 12.601 |
| Résultat brut | 18.346 | 15.833 | 12.172 | 16.637 | 16.177 |
| Total des frais d'exploitation | 28.226 | 28.884 | 30.684 | 25.21 | 35.49 |
| Total des frais de vente/Généraux/Admin | 12.312 | 11.811 | 12.143 | 12.568 | 13.012 |
| Recherche et développement | 2.897 | 2.849 | 2.763 | 3.497 | 3.22 |
| Depreciation / Amortization | 1.388 | 1.63 | 1.572 | 1.454 | 1.466 |
| Charges (revenus) inhabituelles | 0 | 0 | -0.544 | -4.88 | 5.191 |
| Produits d'exploitation | 1.749 | -0.457 | -3.762 | 3.998 | -6.712 |
| Produits (charges) d'intérêts, nets Hors exploitation | -0.974 | -0.9 | -0.749 | -0.515 | -0.384 |
| Autres, nets | 0.432 | 0.465 | -0.179 | -0.062 | 0.078 |
| Résultat net avant impôts | 1.207 | -0.892 | -4.69 | 3.421 | -7.018 |
| Résultat net après impôts | 0.622 | -1.666 | -3.405 | 2.435 | -6.88 |
| Résultat net avant éléments extra | 0.622 | -1.666 | -3.405 | 2.435 | -6.88 |
| Résultat net | 0.622 | -1.666 | -3.405 | 2.435 | -6.88 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | 0.622 | -1.666 | -3.405 | 2.435 | -6.88 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | 0.622 | -1.666 | -3.405 | 2.435 | -6.88 |
| Résultat net dilué | 0.622 | -1.666 | -3.405 | 2.435 | -6.88 |
| Moyenne pondérée des actions diluées | 42.783 | 41.593 | 41.637 | 42.56 | 41.219 |
| BPA dilué hors éléments extraordinaires | 0.01454 | -0.04005 | -0.08178 | 0.05721 | -0.16691 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | 0.01454 | -0.04005 | -0.09027 | -0.01732 | -0.08505 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 51.124 | 61.583 | 51.7 | 53.572 | 57.832 |
| Espèces et placements à court terme | 4.508 | 7.821 | 8.317 | 8.335 | 8.173 |
| Trésorerie et équivalents | 4.508 | 7.821 | 8.317 | 8.335 | 8.173 |
| Total des créances, nettes | 20.177 | 26.175 | 21.121 | 23.176 | 24.572 |
| Accounts Receivable - Trade, Net | 16.705 | 21.834 | 17.766 | 20.704 | 21.463 |
| Total Inventory | 26.439 | 27.587 | 22.262 | 22.061 | 25.087 |
| Other Current Assets, Total | |||||
| Total Assets | 145.36 | 162.344 | 156.254 | 164.87 | 168.613 |
| Property/Plant/Equipment, Total - Net | 9.182 | 10.312 | 11.721 | 13.239 | 5.898 |
| Property/Plant/Equipment, Total - Gross | 24.028 | 24.761 | 28.318 | 28.179 | 23.336 |
| Accumulated Depreciation, Total | -14.846 | -14.449 | -16.597 | -14.94 | -17.438 |
| Goodwill, Net | 56.26 | 57.689 | 58.59 | 57.381 | 57.304 |
| Intangibles, Net | 21.014 | 27.385 | 33.151 | 38.405 | 45.764 |
| Other Long Term Assets, Total | 7.78 | 5.375 | 1.092 | 2.273 | 1.815 |
| Total Current Liabilities | 23.249 | 25.316 | 21.053 | 25.312 | 25.489 |
| Accounts Payable | 6.447 | 4.911 | 5.972 | 5.339 | 7.359 |
| Accrued Expenses | 8.639 | 11.175 | 7.582 | 2.424 | 5.762 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3.811 | 3.235 | 1.721 | 6.9 | 5.982 |
| Other Current Liabilities, Total | 4.352 | 5.995 | 5.778 | 10.649 | 6.386 |
| Total Liabilities | 73.14 | 78.943 | 79.573 | 83.176 | 85.889 |
| Total Long Term Debt | 43.013 | 45.095 | 46.286 | 46.917 | 54.813 |
| Long Term Debt | 43.013 | 45.095 | 46.286 | 46.917 | 54.813 |
| Deferred Income Tax | 0.59 | 1.558 | 1.899 | 1.974 | 2.301 |
| Other Liabilities, Total | 6.288 | 6.974 | 10.335 | 8.973 | 3.286 |
| Total Equity | 72.22 | 83.401 | 76.681 | 81.694 | 82.724 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.454 | 0.452 | 0.444 | 0.438 | 0.436 |
| Additional Paid-In Capital | 229.008 | 225.65 | 232.357 | 229.189 | 226.377 |
| Retained Earnings (Accumulated Deficit) | -142.19 | -132.674 | -132.386 | -124.576 | -119.889 |
| Treasury Stock - Common | 0 | -10.668 | -10.668 | -10.668 | |
| Other Equity, Total | -15.052 | -10.027 | -13.066 | -12.689 | -13.532 |
| Total Liabilities & Shareholders’ Equity | 145.36 | 162.344 | 156.254 | 164.87 | 168.613 |
| Total Common Shares Outstanding | 42.0817 | 41.1429 | 39.4071 | 38.1882 | 37.3788 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 52.449 | 51.124 | 51.818 | 56.498 | 59.448 |
| Espèces et placements à court terme | 3.789 | 4.508 | 5.144 | 4.259 | 5.433 |
| Trésorerie et équivalents | 3.789 | 4.508 | 5.144 | 4.259 | 5.433 |
| Total des créances, nettes | 21.799 | 20.177 | 20.558 | 22.903 | 25.304 |
| Accounts Receivable - Trade, Net | 17.737 | 16.705 | 15.023 | 17.847 | 20.274 |
| Total Inventory | 26.861 | 26.439 | 26.116 | 29.336 | 28.711 |
| Total Assets | 145.578 | 145.36 | 147.013 | 155.273 | 158.044 |
| Property/Plant/Equipment, Total - Net | 8.929 | 9.182 | 9.574 | 9.63 | 10.104 |
| Goodwill, Net | 56.618 | 56.26 | 54.851 | 56.232 | 57.356 |
| Intangibles, Net | 19.641 | 21.014 | 22.464 | 24.219 | 25.878 |
| Other Long Term Assets, Total | 7.941 | 7.78 | 8.306 | 8.694 | 5.258 |
| Total Current Liabilities | 23.217 | 23.249 | 21.36 | 23.354 | 27.226 |
| Accounts Payable | 5.978 | 6.447 | 5.877 | 6.81 | 6.218 |
| Accrued Expenses | 8.356 | 8.639 | 8.165 | 8.192 | 7.725 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.97 | 3.811 | 2.72 | 2.72 | 2.72 |
| Other Current Liabilities, Total | 5.913 | 4.352 | 4.598 | 5.632 | 10.563 |
| Total Liabilities | 71.238 | 73.14 | 75.034 | 77.769 | 81.669 |
| Total Long Term Debt | 41.083 | 43.013 | 46.534 | 45.764 | 46.244 |
| Long Term Debt | 41.083 | 43.013 | 46.534 | 45.764 | 46.244 |
| Deferred Income Tax | 0.546 | 0.59 | 1.181 | 2.427 | 1.442 |
| Other Liabilities, Total | 6.392 | 6.288 | 5.959 | 6.224 | 6.757 |
| Total Equity | 74.34 | 72.22 | 71.979 | 77.504 | 76.375 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.455 | 0.454 | 0.453 | 0.453 | 0.452 |
| Additional Paid-In Capital | 230.108 | 229.008 | 228.229 | 227.413 | 226.203 |
| Retained Earnings (Accumulated Deficit) | -141.568 | -142.19 | -140.524 | -137.119 | -139.554 |
| Treasury Stock - Common | |||||
| Other Equity, Total | -14.655 | -15.052 | -16.179 | -13.243 | -10.726 |
| Total Liabilities & Shareholders’ Equity | 145.578 | 145.36 | 147.013 | 155.273 | 158.044 |
| Total Common Shares Outstanding | 42.19 | 42.0817 | 41.6577 | 41.4997 | 41.2415 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Liquidités provenant des activités d'exploitation | 1.152 | 1.262 | 9.331 | 8.045 | 2.884 |
| Liquidités provenant des activités d'exploitation | 1.453 | 1.781 | 1.922 | 1.987 | 2.423 |
| Amortization | 6.122 | 5.84 | 5.71 | 5.746 | 5.459 |
| Deferred Taxes | -0.414 | -0.33 | -0.143 | -0.398 | -2.861 |
| Éléments non monétaires | 0.791 | 4.449 | 5.546 | 5.355 | 2.46 |
| Cash Taxes Paid | 0.534 | 0.577 | 0.416 | 0.374 | -0.098 |
| Intérêts payés en espèces | 2.314 | 1.577 | 4.881 | 5.496 | 4.987 |
| Variation du fonds de roulement | 2.716 | -10.19 | 4.106 | 0.042 | -1.675 |
| Flux de trésorerie liés aux activités d'investissement | -1.59 | -1.345 | -1.402 | -0.229 | -53.796 |
| Dépenses d'investissement | -1.59 | -1.345 | -1.152 | -1.216 | -1.006 |
| Autres éléments de flux de trésorerie d'investissement, total | -0.25 | 0.987 | -52.79 | ||
| Flux de trésorerie provenant des activités de financement | -2.837 | -0.252 | -7.967 | -7.624 | 53.053 |
| Émission (remboursement) d'actions, nette | 0.577 | 3.314 | 4.557 | ||
| Émission (remboursement) de la dette, nette | -1.786 | 0.05 | -5.597 | -7.403 | 48.496 |
| Effets de change | -0.038 | -0.161 | 0.02 | -0.03 | 0.299 |
| Variation nette de la trésorerie | -3.313 | -0.496 | -0.018 | 0.162 | 2.44 |
| Éléments de flux de trésorerie de financement | -1.628 | -3.616 | -2.37 | -0.221 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 0.622 | -9.516 | -7.85 | -4.445 | -6.88 |
| Cash From Operating Activities | 1.812 | 1.152 | -1.527 | -2.176 | -1.986 |
| Cash From Operating Activities | 0.333 | 1.453 | 1.122 | 0.758 | 0.382 |
| Amortization | 1.388 | 6.122 | 4.492 | 2.92 | 1.466 |
| Non-Cash Items | 0.765 | 0.791 | -0.289 | -1.498 | 0.97 |
| Cash Taxes Paid | -0.134 | 0.534 | 0.493 | 0.352 | 0.107 |
| Cash Interest Paid | 1.172 | 2.314 | 1.529 | 0.845 | 0.383 |
| Changes in Working Capital | -1.296 | 2.716 | 1.158 | -0.951 | 2.076 |
| Cash From Investing Activities | 0.288 | -1.59 | -1.355 | -0.913 | -0.471 |
| Capital Expenditures | -0.224 | -1.59 | -1.355 | -0.913 | -0.471 |
| Cash From Financing Activities | -2.893 | -2.837 | -0.107 | -0.484 | 0.094 |
| Financing Cash Flow Items | -0.156 | -1.628 | -1.167 | -0.78 | -0.501 |
| Issuance (Retirement) of Stock, Net | 0.104 | 0.577 | 0.346 | 0.282 | 0.031 |
| Issuance (Retirement) of Debt, Net | -2.841 | -1.786 | 0.714 | 0.014 | 0.564 |
| Foreign Exchange Effects | 0.074 | -0.038 | 0.312 | 0.011 | -0.025 |
| Net Change in Cash | -0.719 | -3.313 | -2.677 | -3.562 | -2.388 |
| Deferred Taxes | -0.414 | -0.16 | 1.04 | ||
| Other Investing Cash Flow Items, Total | 0.512 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| B. Riley Asset Management, LLC | Investment Advisor/Hedge Fund | 8.0796 | 3408796 | 221500 | 2023-03-31 | MED |
| Punch & Associates Investment Management, Inc. | Investment Advisor/Hedge Fund | 6.9858 | 2947329 | 183290 | 2023-03-31 | |
| Harvey Partners, LLC | Hedge Fund | 6.4297 | 2712700 | -198800 | 2023-03-31 | |
| AMH Equity, Ltd. | Hedge Fund | 4.8682 | 2053907 | 0 | 2023-03-31 | MED |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 4.1364 | 1745133 | 3985 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1337 | 1743996 | 486198 | 2023-03-31 | LOW |
| Green (James W) | Individual Investor | 3.6219 | 1528067 | 634619 | 2023-03-21 | LOW |
| Royce Investment Partners | Investment Advisor/Hedge Fund | 3.4112 | 1439182 | 14319 | 2023-03-31 | LOW |
| Granahan Investment Management, Inc. | Investment Advisor | 3.3898 | 1430151 | -32306 | 2023-03-31 | LOW |
| Archon Capital Management LLC | Hedge Fund | 3.2277 | 1361769 | 0 | 2023-03-31 | |
| Boothbay Fund Management, LLC | Investment Advisor/Hedge Fund | 2.9275 | 1235098 | 162269 | 2023-03-31 | HIGH |
| Heartland Advisors, Inc. | Investment Advisor/Hedge Fund | 2.8443 | 1200000 | 85601 | 2023-03-31 | |
| Meros Investment Management, LP | Investment Advisor | 2.6646 | 1124206 | -12639 | 2023-03-31 | |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.6197 | 1105253 | 0 | 2023-03-31 | MED |
| Portolan Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.4734 | 1043546 | -10754 | 2023-03-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.0457 | 863075 | -550 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.7303 | 730007 | -4300 | 2023-03-31 | HIGH |
| Florida State Board of Administration | Pension Fund | 1.5231 | 642604 | 535604 | 2022-09-30 | LOW |
| Monarch Partners Asset Management LLC | Investment Advisor/Hedge Fund | 1.4549 | 613837 | -187422 | 2022-12-31 | |
| JP Morgan Asset Management | Investment Advisor | 1.2399 | 523120 | 0 | 2023-03-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group530K+
Tradeurs
87K+
Clients actifs par mois
$46M+
Volume d'investissement par mois
$31M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Harvard Bioscience Company profile
À propos de Harvard Bioscience
Harvard Bioscience, Inc. est un développeur, fabricant et vendeur de technologies, de produits et de services qui permettent la recherche fondamentale, la découverte et les tests précliniques pour le développement de médicaments. La société fournit des produits qui soutiennent la recherche dans six classes différentes d'utilisation en laboratoire, y compris les molécules, les cellules, les tissus, les organes, les organismes et les cliniques. La société vend principalement ses produits sous plusieurs marques, notamment Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX et MCS. Les clients de la société comprennent des sociétés pharmaceutiques et biotechnologiques, ainsi que des organismes de recherche sous contrat, des laboratoires universitaires et des chercheurs du gouvernement.
| Industry: | Advanced Medical Equipment & Technology (NEC) |
84 October Hill Rd
HOLLISTON
MASSACHUSETTS 01746-1371
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 530 000 traders du monde entier qui ont choisi de trader avec Capital.com